Tejara Capital’s Pacira BioSciences PCRX Stock Holding History

Tejara Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-20,000	Closed	-$584K	–	81
2024 Q1	$584K	Buy	+20,000	New	+$614K	0.21%	61

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tejara Capital's PCRX Position: Q2 2024 in Review

Tejara Capital sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 20,000 shares — an estimated $584K sold.

Tejara Capital first reported a position in PCRX in Q1 2024 and held it in 1 quarter. The position peaked at $584K in Q1 2024. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

Tejara Capital reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
Tejara Capital sold 20,000 Pacira BioSciences shares in Q2 2024, an estimated $584K.
Tejara Capital first reported a position in Pacira BioSciences in Q1 2024 and held it in 1 quarter.
Tejara Capital's Pacira BioSciences position peaked at $584K in Q1 2024.
280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Tejara Capital's 13F filing for Q2 2024, filed 14 Aug 2024.